109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
帕里辛通过调节 ACSL4/p-Smad3/PGC-1α 通路预防脓毒症诱导的肠损伤：生物信息学与实验验证相结合的方法
Authors Bao D, Shao S, Wang Y, Chen X, Ren Y, Zhou C, Mao Q
Received 12 June 2025
Accepted for publication 8 October 2025
Published 15 October 2025 Volume 2025:18 Pages 14283—14305
DOI https://doi.org/10.2147/JIR.S546492
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tara Strutt
Daiqin Bao,1,* Shifeng Shao,2,* Yingjie Wang,3,* Xian Chen,1 Yunqin Ren,1 Chaomin Zhou,1 Qingxiang Mao1
1Department of Anesthesiology, Daping Hospital, Army Medical University, Chongqing, 400042, People’s Republic of China; 2Department of ICU, Daping Hospital, Army Medical University, Chongqing, 400042, People’s Republic of China; 3Department of Post-Graduate School, Army Medical University, Chongqing, 400042, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qingxiang Mao, Department of Anesthesiology, Daping Hospital, Army Medical University, Chongqing, 400042, People’s Republic of China, Email qxmao@tmmu.edu.cn
Background: Sepsis is a major clinical challenge, with in-hospital mortality of 25%-40% in intensive care unit patients. The gastrointestinal tract is recognized as both the “initiating organ” of multiple organ dysfunction syndrome and the “central organ” in orchestrating the host stress response during critical illness. ACSL4, a regulator of lipid metabolism and ferroptosis, is a potential target for sepsis-induced intestinal injury, but its inhibitor parishin has not been evaluated in this context.
Methods: Key genes implicated in sepsis pathogenesis were identified through bioinformatic analysis of publicly available datasets from the GEO. Network pharmacology approaches were used to screen for small-molecule compounds with high binding affinity to the identified hub genes. Molecular docking, followed by in vivo and in vitro validation, was employed to evaluate the therapeutic efficacy and mechanistic impact of the top candidate compound in a murine sepsis model.
Results: Weighted Gene Co-expression Network Analysis identified five genes most significantly associated with sepsis diagnosis. Protein-protein interaction network analysis revealed 157 hub genes, among which ACSL4 was the sole gene shared across diagnostic and functional modules. Molecular docking analysis indicated that Parishin exhibited the strongest binding affinity to ACSL4 (docking score: − 17.701). In septic animal models, ACSL4 expression was markedly upregulated in both plasma monocytes and intestinal tissues (P < 0.05), accompanied by increased levels of inflammatory cytokines, lipid peroxidation (LPO), MDA, and Fe2+ (P < 0.05). Expression of ferroptosis-associated proteins was also evidently elevated (P < 0.05). Treatment with Parishin notably attenuated these pathological changes, reduced ferroptosis-related markers, and improved 72-hour survival rates in septic mice (P < 0.05).
Conclusion: Parishin ameliorates sepsis-induced intestinal injury by downregulating ACSL4 expression, thereby inhibiting Smad3 phosphorylation and suppressing ferroptosis. These findings suggest that ACSL4 is a promising therapeutic target for mitigating intestinal damage in sepsis.
Keywords: sepsis, parishin, acsl4, ferroptosis, mitochondrial function
1Department of Anesthesiology, Daping Hospital, Army Medical University, Chongqing, 400042, People’s Republic of China; 2Department of ICU, Daping Hospital, Army Medical University, Chongqing, 400042, People’s Republic of China; 3Department of Post-Graduate School, Army Medical University, Chongqing, 400042, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qingxiang Mao, Department of Anesthesiology, Daping Hospital, Army Medical University, Chongqing, 400042, People’s Republic of China, Email qxmao@tmmu.edu.cn
Background: Sepsis is a major clinical challenge, with in-hospital mortality of 25%-40% in intensive care unit patients. The gastrointestinal tract is recognized as both the “initiating organ” of multiple organ dysfunction syndrome and the “central organ” in orchestrating the host stress response during critical illness. ACSL4, a regulator of lipid metabolism and ferroptosis, is a potential target for sepsis-induced intestinal injury, but its inhibitor parishin has not been evaluated in this context.
Methods: Key genes implicated in sepsis pathogenesis were identified through bioinformatic analysis of publicly available datasets from the GEO. Network pharmacology approaches were used to screen for small-molecule compounds with high binding affinity to the identified hub genes. Molecular docking, followed by in vivo and in vitro validation, was employed to evaluate the therapeutic efficacy and mechanistic impact of the top candidate compound in a murine sepsis model.
Results: Weighted Gene Co-expression Network Analysis identified five genes most significantly associated with sepsis diagnosis. Protein-protein interaction network analysis revealed 157 hub genes, among which ACSL4 was the sole gene shared across diagnostic and functional modules. Molecular docking analysis indicated that Parishin exhibited the strongest binding affinity to ACSL4 (docking score: − 17.701). In septic animal models, ACSL4 expression was markedly upregulated in both plasma monocytes and intestinal tissues (P < 0.05), accompanied by increased levels of inflammatory cytokines, lipid peroxidation (LPO), MDA, and Fe2+ (P < 0.05). Expression of ferroptosis-associated proteins was also evidently elevated (P < 0.05). Treatment with Parishin notably attenuated these pathological changes, reduced ferroptosis-related markers, and improved 72-hour survival rates in septic mice (P < 0.05).
Conclusion: Parishin ameliorates sepsis-induced intestinal injury by downregulating ACSL4 expression, thereby inhibiting Smad3 phosphorylation and suppressing ferroptosis. These findings suggest that ACSL4 is a promising therapeutic target for mitigating intestinal damage in sepsis.
Keywords: sepsis, parishin, acsl4, ferroptosis, mitochondrial function